Divis Laboratories Ltd
Pharmaceuticals & Biotechnology | Large Cap
Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Overvalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio8.40
- Profitability Ratio10.00
- Efficiency Ratio2.33
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio9.20
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Overall Valuation Score
P/E RATIO (TTM)
68.67
Industry Median
28.62
Large Cap Median
30.25
P/E RATIO
69.71
P/B RATIO
10.69
Industry Median
3.17
Large Cap Median
5.04
P/S RATIO
16.61
Industry Median
3.42
Large Cap Median
5.48
Others
PEG RATIO
13.15
EV/EBITDA RATIO
44.39
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹6743 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates excellent growth across all key metrics. Strong revenue growth indicates increasing market demand and effective sales strategies. High operating profit growth reflects efficient cost management. Robust EPS and net income growth confirm enhanced profitability. Significant asset growth suggests strategic investments and expansion. These consistent high-growth rates position the company favorably for future success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 28.57 | -13.3 | 0.99 | 19.31 | 12.82 |
| Operating Profit Growth Rate | 35.51 | -39 | -6.75 | 34.52 | 15.74 |
| Earnings Per Share (EPS) Growth | 49.19 | -38.41 | -12.26 | 36.93 | 17.21 |
| Asset Growth Rate | 24.04 | 7.97 | 7.18 | 9.45 | 18.39 |
| Net Income Growth Rate | 49.19 | -38.41 | -12.23 | 36.94 | 17.21 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company demonstrates solid financial performance across key metrics. High adjusted and cash earnings per share (EPS) reflect strong profitability. An increasing book value per share indicates growing equity and shareholder value. Consistent dividend payments show a commitment to shareholder returns. However, relatively high capital expenditures may warrant monitoring to ensure effective investment and return on investment.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 111.77 | 68.83 | 60.49 | 82.64 | 98.98 |
| Cash Earnings Per Share (Cash EPS) | 123.47 | 81.74 | 74.64 | 97.85 | 114.38 |
| Book Value Per Share | 442.57 | 481.77 | 512.11 | 564.87 | 632.49 |
| Dividend Per Share (DPS) | 30.11 | 30.22 | 30.14 | 29.71 | 29.99 |
| Capital Expenditures (CapEx) | 713 | 473 | 1003 | 1438 | 2517 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability, characterized by high margins and returns. Strong gross profit and operating margins indicate efficient production and cost management. High returns on capital employed, equity, and assets demonstrate the company's ability to generate profits from its investments. These metrics reflect a highly profitable and well-managed operation.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.88 | 26.09 | 23.35 | 27.47 | 28.2 |
| Return on Capital Employed (ROCE) | 35 | 19 | 16 | 20 | 22 |
| Return on Equity (ROE) | 25.24 | 14.28 | 11.79 | 14.64 | 15.32 |
| Return on Assets (ROA) | 29.08 | 16.43 | 14.29 | 17.57 | 17.18 |
| Operating Margin | 43.36 | 30.51 | 28.17 | 31.76 | 32.59 |
| Net Margin | 33.04 | 23.47 | 20.4 | 23.41 | 24.32 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios suggest challenges in optimizing asset utilization. Low fixed asset and capital turnover ratios indicate that the company is not generating substantial revenue from its fixed assets or overall capital. High days sales in inventory and receivable days reflect difficulties in managing inventory and collecting payments, which may tie up significant capital. Improving these metrics could enhance operational performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.07 | 1.64 | 1.66 | 1.72 | 1.62 |
| Inventory Turnover Ratio | 2.17 | 1.97 | 1.94 | 2.11 | 2.11 |
| Receivables Turnover Ratio | 4.37 | 3.68 | 3.97 | 3.83 | 3.7 |
| Days Sales in Inventory Ratio | 168.2 | 185.28 | 188.14 | 172.99 | 172.99 |
| Receivable Days | 83.52 | 99.18 | 91.94 | 95.3 | 98.65 |
| Capital Turnover Ratio | 0.76 | 0.61 | 0.58 | 0.63 | 0.63 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company maintains strong coverage ratios, highlighting its ability to meet its financial obligations. An exceptionally high-interest coverage ratio demonstrates the company's capacity to cover interest expenses, indicating low financial risk. The equity dividend coverage ratio suggests the company can comfortably meet its dividend payments, ensuring shareholder returns. Overall, the company exhibits robust financial security.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 1843 | 1185.5 | 541.75 | 973 | 148.3 |
| Equity Dividend Coverage Ratio | 3.7 | 2.27 | 2 | 2.78 | 3.23 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, characterized by a complete absence of debt. This debt-free structure provides a strong financial foundation. The equity ratio of 1.0 signifies that the company's assets are entirely financed by equity, eliminating financial risk. This conservative approach ensures long-term stability and resilience against economic downturns.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0 | 0 |
| Equity Ratio | 1 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is strong. High current and quick ratios indicate the company's ability to meet its short-term liabilities with ease. A substantial cash ratio further supports this, reflecting plentiful liquid assets. The operating cash flow ratio suggests the company generates adequate cash from its operations, though there is room for improvement.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 5.22 | 5.69 | 5.23 | 5.33 | 3.47 |
| Quick Ratio | 3.48 | 3.88 | 3.54 | 3.67 | 2.26 |
| Cash Ratio | 1.73 | 2.55 | 2.11 | 1.91 | 1.05 |
| Operating Cash Flow Ratio | 1.17 | 1.49 | 0.67 | 0.85 | 0.84 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Divis Laboratories Ltd | 7.91 | 69.71 | Highly Overvalued | 3441.00 | 98.20 | 2568.00 |
| 2 | Lupin Ltd | 7.84 | 20.16 | Neutral | 8816.00 | 139.25 | 5355.00 |
| 3 | Cipla Ltd | 7.62 | 28.15 | Neutral | 5883.00 | 43.52 | 3862.00 |
| 4 | Mankind Pharma Ltd | 7.61 | 52.10 | Highly Overvalued | 3617.00 | 49.34 | 1938.00 |
| 5 | Zydus Lifesciences Ltd | 7.60 | 21.38 | Neutral | 8475.00 | 35.38 | 5124.00 |
| 6 | Dr Reddys Laboratories Ltd | 6.49 | 25.31 | Neutral | 6454.00 | 38.58 | 4158.00 |
The management of Divis Laboratories demonstrates a mixed performance. Revenue and profit growth have seen fluctuations, with a recent rise in sales but inconsistencies in profitability. Capital efficiency, as indicated by ROCE and ROE, has decreased. The company maintains a conservative debt level, and promoter holding remains strong, indicating alignment with shareholder interests. Recent increase in FII holding also signifies positive sentiment. However, declining OPM raises concerns about operational efficiency. Overall, the management's effectiveness presents a mixed picture, requiring careful monitoring of profitability and operational efficiency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 51.89% | Strong Promoter Confidence |
| FII Holding | 18.01% | Increasing Institutional Interest | |
| CONS | Operating Profit Margin | 32% | Declining OPM trend |
| Return on Capital Employed | 20% | Declining ROCE trend |
Financial Performance & Growth
Divis Laboratories has demonstrated fluctuating financial performance. While sales growth has been positive, profit growth has been inconsistent, and operating profit margin has seen decline.
Sales Growth Analysis:
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth % | 20.77% | 8.49% | 28.56% | -13.31% | 1.00% | 19.31% |
Profit Growth Analysis:
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Profit Growth % | 19.37% | 12.69% | 28.56% | -38.35% | -12.38% | 36.94% |
Operating Profit Margin (OPM):
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| OPM % | 38% | 35.67% | 42.33% | 31% | 28% | 32% |
The company's OPM % has shown a decreasing trend in recent years compared to previous performance. The OPM has decreased from 43% in Mar 2022 to 32% in Mar 2025.
Capital Efficiency & Returns
The capital efficiency and returns of Divis Laboratories have shown a declining trend, indicating less effective utilization of capital and shareholder funds.
Return on Capital Employed (ROCE):
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 35% | 26.67% | 33.67% | 19% | 16% | 20% |
Return on Equity (ROE):
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE % | 34.57% | 20.57% | 25.87% | 14% | 12% | 15% |
The ROCE % has decreased from 35% (2014-2016) to 20% in Mar 2025. The ROE % has decreased from 34.57% (2014-2016) to 15% in Mar 2025.
Financial Health & Prudence
Divis Laboratories maintains a strong financial health profile with prudent debt management and consistent dividend payouts.
Debt Management:
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Borrowings | 18 | 27 | 42 | 36 | 63 | 106 | 39 | 5 | 4 | 4 | 3 | 4 |
Dividend Payout:
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Dividend Payout % | 29.67% | 28.67% | 27% | 44% | 50% | 36% |
The company has maintained a low debt level. The company has been consistently sharing profits with shareholders through dividend payouts.
Shareholding & Ownership Structure
The shareholding and ownership structure of Divis Laboratories indicates strong promoter confidence and increasing institutional interest.
Promoter Holding:
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 52.07% | 52.05% | 52.01% | 51.97% | 51.95% | 51.94% | 51.94% | 51.92% | 51.89% |
Institutional Holding (FII/DII):
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FIIs + | 17.22% | 18.41% | 21.21% | 19.08% | 19.87% | 18.45% | 14.67% | 14.68% | 18.01% |
| DIIs + | 14.20% | 15.77% | 14.22% | 15.59% | 16.74% | 18.32% | 21.00% | 22.10% | 20.63% |
The promoters consistently hold a significant portion of the company's shares. The increasing FII holding indicates growing confidence from foreign investors.
Divis Laboratories faces moderate risk due to fluctuations in financial performance metrics and a declining trend in capital efficiency. While sales growth has shown recent improvement, inconsistencies in profit growth and a decreasing Operating Profit Margin (OPM) raise concerns about operational efficiency. The company maintains a conservative debt level and exhibits strong promoter holding, which help mitigate financial and ownership-related risks. However, the declining Return on Capital Employed (ROCE) and Return on Equity (ROE) indicate potential challenges in maximizing returns from capital investments. Overall, Divis Laboratories requires careful risk management to address profitability and efficiency concerns.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106745.75Bullish
- SMA 206701.80Bullish
- SMA 506675.07Bullish
- EMA 106734.28Bullish
- EMA 206714.00Bullish
- EMA 506687.91Bullish
- DEMA 106755.57Bearish
- DEMA 206744.42Bullish
- DEMA 506708.38Bullish
- TEMA 106755.72Bearish
- TEMA 206759.06Bearish
- TEMA 506732.49Bullish
- MACD23.92Bullish
- ADX27.47Strong Trend
- IndicatorValueSignal
- RSI61.17Neutral
- CCI68.36Neutral
- ROC 90.91Bullish
- ROC 141.35Bullish
- ROC 251.22Bullish
- Stoch K67.19Neutral
- Stoch D66.88Neutral
- IndicatorValueSignal
- BB Upper6796.39Neutral
- BB Middle6701.80Neutral
- BB Lower6607.21Neutral
- ATR37.12Low Volatility
- IndicatorValueSignal
- MFI52.54Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106713.30Bullish
- SMA 206681.38Bullish
- SMA 506660.07Bullish
- EMA 106723.59Bullish
- EMA 206699.91Bullish
- EMA 506680.54Bullish
- DEMA 106753.62Bearish
- DEMA 206730.88Bullish
- DEMA 506688.90Bullish
- TEMA 106763.00Bearish
- TEMA 206750.77Bearish
- TEMA 506694.45Bullish
- MACD25.48Bullish
- ADX23.72Weak Trend
- IndicatorValueSignal
- RSI59.16Neutral
- CCI91.48Neutral
- ROC 91.40Bullish
- ROC 141.48Bullish
- ROC 251.50Bullish
- Stoch K76.10Neutral
- Stoch D80.28Overbought
- IndicatorValueSignal
- BB Upper6797.86Neutral
- BB Middle6681.38Neutral
- BB Lower6564.89Neutral
- ATR52.04Low Volatility
- IndicatorValueSignal
- MFI42.38Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106684.95Bullish
- SMA 206674.77Bullish
- SMA 506710.41Bullish
- EMA 106701.67Bullish
- EMA 206683.67Bullish
- EMA 506658.93Bullish
- DEMA 106731.41Bullish
- DEMA 206698.06Bullish
- DEMA 506745.72Bullish
- TEMA 106748.17Bullish
- TEMA 206720.22Bullish
- TEMA 50N/AN/A
- MACD15.25Bullish
- ADX19.57Weak Trend
- IndicatorValueSignal
- RSI56.32Neutral
- CCI106.25Overbought
- ROC 91.93Bullish
- ROC 141.27Bullish
- ROC 252.52Bullish
- Stoch K79.96Neutral
- Stoch D65.15Neutral
- IndicatorValueSignal
- BB Upper6803.98Neutral
- BB Middle6674.77Neutral
- BB Lower6545.57Neutral
- ATR86.81Low Volatility
- IndicatorValueSignal
- MFI43.93Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106670.05Bullish
- SMA 206672.20Bullish
- SMA 506568.44Bullish
- SMA 1006359.66Bullish
- SMA 2006347.59Bullish
- EMA 106688.16Bullish
- EMA 206673.02Bullish
- EMA 506575.94Bullish
- EMA 1006469.04Bullish
- EMA 2006356.76Bullish
- DEMA 106708.54Bullish
- DEMA 206711.12Bullish
- DEMA 506731.52Bullish
- DEMA 1006606.77Bullish
- DEMA 2006595.55Bullish
- TEMA 106733.13Bullish
- TEMA 206676.47Bullish
- TEMA 506787.13Bearish
- TEMA 1006694.13Bullish
- TEMA 2006503.01Bullish
- MACD26.77Bullish
- ADX22.78Weak Trend
- IndicatorValueSignal
- RSI55.09Neutral
- CCI72.07Neutral
- ROC 142.89Bullish
- ROC 25-2.58Bearish
- Stoch K73.51Neutral
- Stoch D64.74Neutral
- IndicatorValueSignal
- BB Upper6860.88Neutral
- BB Middle6672.20Neutral
- BB Lower6483.52Neutral
- ATR144.81Low Volatility
- IndicatorValueSignal
- MFI65.36Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 206339.90Bullish
- SMA 506357.55Bullish
- EMA 206450.65Bullish
- EMA 506288.04Bullish
- DEMA 206579.54Bullish
- DEMA 506605.45Bullish
- TEMA 206667.36Bearish
- TEMA 506478.69Bullish
- MACD112.44Bullish
- ADX13.57Weak Trend
- IndicatorValueSignal
- RSI55.55Neutral
- CCI80.67Neutral
- ROC 144.88Bullish
- ROC 252.46Bullish
- Stoch K75.36Neutral
- Stoch D80.71Overbought
- IndicatorValueSignal
- BB Upper6918.89Neutral
- BB Middle6339.90Neutral
- BB Lower5760.91Neutral
- ATR320.37Low Volatility
- IndicatorValueSignal
- MFI60.17Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 66328.08Bullish
- SMA 126367.46Bullish
- SMA 246006.66Bullish
- EMA 66398.11Bullish
- EMA 126266.10Bullish
- EMA 245862.38Bullish
- DEMA 66496.53Bullish
- DEMA 126573.31Bullish
- DEMA 246661.93Bullish
- TEMA 66527.62Bullish
- TEMA 126451.20Bullish
- TEMA 246726.47Bearish
- MACD927.80Bearish
- ADX22.94Weak Trend
- IndicatorValueSignal
- RSI61.02Neutral
- CCI110.25Overbought
- ROC 2566.58Bullish
- ROC 5051.45Bullish
- Stoch K80.74Overbought
- Stoch D86.03Overbought
- IndicatorValueSignal
- BB Upper6981.11Neutral
- BB Middle6205.15Neutral
- BB Lower5429.20Neutral
- ATR665.63Low Volatility
- IndicatorValueSignal
- MFI68.66Neutral